nach oben

Acta Neurochirurgica

Erschienen in:

01.10.2010 | Clinical Article

Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas

verfasst von: Daniel Coluccia, Javier Fandino, Masayuki Fujioka, Susanne Cordovi, Carl Muroi, Hans Landolt

Erschienen in: Acta Neurochirurgica | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Object

5-aminolevulinic acid (5-ALA) has gained importance as an intraoperative photodynamic diagnostic agent for the extirpation of malignant gliomas. The application of this technique for resection of meningiomas has barely been explored. The aim of this study was to evaluate the utility of 5-ALA-induced fluorescence as a visual tool in meningioma resection and its correlation with histological findings.

Methods

A total of 33 consecutive patients undergoing resection of intracranial meningiomas from December 2007 to August 2009 were included in this study. After confirmation of normal liver function, 5-ALA was administered orally (20 mg/kg) within 3–5 h prior to skin incision. All cases were operated on using standard microsurgical and neuronavigation-guided techniques. Intraoperative 440 nm fluorescence was applied periodically during and at the end of resection in order to detect tumor-infiltrated sites. The fluorescence of the tumor was evaluated intraoperatively by the surgeon and confirmed by subsequent video analysis.

Results

A total of 32 (97%) patients presented with benign meningiomas (WHO I–II). In 1 (3%) patient, histological anaplastic signs (WHO III) could be demonstrated. 5-ALA-induced fluorescence of the tumor was confirmed in a total of 31 (94%) patients. The fluorescence did not correlate with the histological findings (n = 30 WHO I–II, n = 1 WHO grade III) or with preoperative brain edema and administration of steroids. A total resection could be postoperatively demonstrated in 25 (76%) patients. No adverse effects attributable to 5-ALA occurred.

Conclusions

5-ALA-induced fluorescence is a useful and promising intraoperative tool for the visualization of meningioma tissue. The novel findings demonstrated in this study in terms of high fluorescence and poor correlation with histological findings highlight the usefulness of this technique as a routine visual tool to achieve optimal resection of meningiomas.

Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, Curry WT Jr, Barker FG 2nd (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64:56–60, discussion 60CrossRefPubMed

Ayerbe J, Lobato RD, de la Cruz J, Alday R, Rivas JJ, Gomez PA, Cabrera A (1999) Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir (Wien) 141:921–932CrossRef

Bitzer M, Nagele T, Geist-Barth B, Klose U, Gronewaller E, Morgalla M, Heiss E, Voigt K (2000) Role of hydrodynamic processes in the pathogenesis of peritumoral brain edema in meningiomas. J Neurosurg 93:594–604CrossRefPubMed

Bondy M, Ligon BL (1996) Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol 29:197–205CrossRefPubMed

Brown M, Schrot R, Bauer K, Letendre D (2009) Incidence of first primary central nervous system tumors in California, 2001–2005. J Neurooncol 94(2):249–261CrossRefPubMed

Chan RC, Thompson GB (1984) Morbidity, mortality, and quality of life following surgery for intracranial meningiomas. A retrospective study in 257 cases. J Neurosurg 60:52–60CrossRefPubMed

Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM (2005) Epidemiology of intracranial meningioma. Neurosurgery 57:1088–1095, discussion 1088–1095CrossRefPubMed

Colombo F, Casentini L, Cavedon C, Scalchi P, Cora S, Francescon P (2009) Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients. Neurosurgery 64:A7–A13CrossRefPubMed

Duffner F, Ritz R, Freudenstein D, Weller M, Dietz K, Wessels J (2005) Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX. J Neurooncol 71:107–111CrossRefPubMed

10.

El-Sharabasy MM, El-Waseef AM, Hafez MM, Salim SA (1992) Porphyrin metabolism in some malignant diseases. Br J Cancer 65:409–412PubMed

11.

Ennis SR, Novotny A, Xiang J, Shakui P, Masada T, Stummer W, Smith DE, Keep RF (2003) Transport of 5-aminolevulinic acid between blood and brain. Brain Res 959:226–234CrossRefPubMed

12.

Fotinos N, Campo MA, Popowycz F, Gurny R, Lange N (2006) 5-Aminolevulinic acid derivatives in photomedicine: characteristics, application and perspectives. Photochem Photobiol 82:994–1015CrossRefPubMed

13.

Gabeau-Lacet D, Aghi M, Betensky RA, Barker FG, Loeffler JS, Louis DN (2009) Bone involvement predicts poor outcome in atypical meningioma. J Neurosurg 111(3):464–471CrossRefPubMed

14.

Hebeda KM, Saarnak AE, Olivo M, Sterenborg HJ, Wolbers JG (1998) 5-Aminolevulinic acid induced endogenous porphyrin fluorescence in 9L and C6 brain tumours and in the normal rat brain. Acta Neurochir (Wien) 140:503–512, discussion 512–503CrossRef

15.

Hoffman S, Propp JM, McCarthy BJ (2006) Temporal trends in incidence of primary brain tumors in the United States, 1985–1999. Neuro Oncol 8:27–37CrossRefPubMed

16.

Iinuma S, Farshi SS, Ortel B, Hasan T (1994) A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin. Br J Cancer 70:21–28PubMed

17.

Ildan F, Erman T, Gocer AI, Tuna M, Bagdatoglu H, Cetinalp E, Burgut R (2007) Predicting the probability of meningioma recurrence in the preoperative and early postoperative period: a multivariate analysis in the midterm follow-up. Skull Base 17:157–171CrossRefPubMed

18.

Inamura T, Nishio S, Takeshita I, Fujiwara S, Fukui M (1992) Peritumoral brain edema in meningiomas—influence of vascular supply on its development. Neurosurgery 31:179–185CrossRefPubMed

19.

Jaaskelainen J (1986) Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 26:461–469CrossRefPubMed

20.

Jaaskelainen J, Haltia M, Servo A (1986) Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 25:233–242CrossRefPubMed

21.

Jennett B, Bond M (1975) Assessment of outcome after severe brain damage. Lancet 1:480–484CrossRefPubMed

22.

Johnson WD, Loredo LN, Slater JD (2008) Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors. Neurosurg Focus 24:E2CrossRefPubMed

23.

Kajimoto Y, Kuroiwa T, Miyatake S, Ichioka T, Miyashita M, Tanaka H, Tsuji M (2007) Use of 5-aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence. Case report. J Neurosurg 106:1070–1074CrossRefPubMed

24.

Kantelhardt SR, Diddens H, Leppert J, Rohde V, Huttmann G, Giese A (2008) Multiphoton excitation fluorescence microscopy of 5-aminolevulinic acid induced fluorescence in experimental gliomas. Lasers Surg Med 40:273–281CrossRefPubMed

25.

Kennedy JC, Pottier RH (1992) Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 14:275–292CrossRefPubMed

26.

Kollova A, Liscak R, Novotny J Jr, Vladyka V, Simonova G, Janouskova L (2007) Gamma knife surgery for benign meningioma. J Neurosurg 107:325–336CrossRefPubMed

27.

Krammer B, Plaetzer K (2008) ALA and its clinical impact, from bench to bedside. Photochem Photobiol Sci 7:283–289CrossRefPubMed

28.

Little KM, Friedman AH, Sampson JH, Wanibuchi M, Fukushima T (2005) Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients. Neurosurgery 56:546–559, discussion 546–559CrossRefPubMed

29.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109CrossRefPubMed

30.

Madsen C, Schroder HD (1997) Ki-67 immunoreactivity in meningiomas—determination of the proliferative potential of meningiomas using the monoclonal antibody Ki-67. Clin Neuropathol 16:137–142PubMed

31.

Morofuji Y, Matsuo T, Hayashi Y, Suyama K, Nagata I (2008) Usefulness of intraoperative photodynamic diagnosis using 5-aminolevulinic acid for meningiomas with cranial invasion: technical case report. Neurosurgery 62:102–103, discussion 103–104CrossRefPubMed

32.

Morokoff AP, Zauberman J, Black PM (2008) Surgery for convexity meningiomas. Neurosurgery 63:427–433, discussion 433–424CrossRefPubMed

33.

Mustajoki P, Timonen K, Gorchein A, Seppalainen AM, Matikainen E, Tenhunen R (1992) Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms. Eur J Clin Investig 22:407–411CrossRef

34.

Nakano T, Asano K, Miura H, Itoh S, Suzuki S (2002) Meningiomas with brain edema: radiological characteristics on MRI and review of the literature. Clin Imaging 26:243–249CrossRefPubMed

35.

Nakasu S, Fukami T, Jito J, Nozaki K (2009) Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol 26:69–72CrossRefPubMed

36.

Novotny A, Xiang J, Stummer W, Teuscher NS, Smith DE, Keep RF (2000) Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J Neurochem 75:321–328CrossRefPubMed

37.

Olivo M, Wilson BC (2004) Mapping ALA-induced PPIX fluorescence in normal brain and brain tumour using confocal fluorescence microscopy. Int J Oncol 25:37–45PubMed

38.

Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM (1997) 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol 65:235–251CrossRefPubMed

39.

Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM (1997) 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 79:2282–2308CrossRefPubMed

40.

Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21:1455–1465CrossRefPubMed

41.

Simis A, de Aguiar PH Pires, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ (2008) Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol 70:471–477, discussion 477CrossRefPubMed

42.

Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22–39CrossRefPubMed

43.

Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, Shaw EG (1998) Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 73:936–942CrossRefPubMed

44.

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401CrossRefPubMed

45.

Stummer W, Stepp H, Moller G, Ehrhardt A, Leonhard M, Reulen HJ (1998) Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien) 140:995–1000CrossRef

46.

Stummer W, Stocker S, Novotny A, Heimann A, Sauer O, Kempski O, Plesnila N, Wietzorrek J, Reulen HJ (1998) In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol B 45:160–169CrossRefPubMed

47.

Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C, Goetz AE, Kiefmann R, Reulen HJ (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42:518–525, discussion 525–516CrossRefPubMed

48.

Terr L, Weiner LP (1983) An autoradiographic study of delta-aminolevulinic acid uptake by mouse brain. Exp Neurol 79:564–568CrossRefPubMed

49.

Tsai JC, Hsiao YY, Teng LJ, Chen CT, Kao MC (1999) Comparative study on the ALA photodynamic effects of human glioma and meningioma cells. Lasers Surg Med 24:296–305CrossRefPubMed

50.

Utsuki S, Oka H, Sato S, Shimizu S, Suzuki S, Tanizaki Y, Kondo K, Miyajima Y, Fujii K (2007) Histological examination of false positive tissue resection using 5-aminolevulinic acid-induced fluorescence guidance. Neurol Med Chir (Tokyo) 47:210–213, discussion 213–214CrossRef

51.

Webber J, Kessel D, Fromm D (1997) Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid. J Photochem Photobiol B 37:151–153CrossRefPubMed

Titel: Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas
verfasst von: Daniel Coluccia
Javier Fandino
Masayuki Fujioka
Susanne Cordovi
Carl Muroi
Hans Landolt
Publikationsdatum: 01.10.2010
Verlag: Springer Vienna
Erschienen in: Acta Neurochirurgica / Ausgabe 10/2010
Print ISSN: 0001-6268
Elektronische ISSN: 0942-0940
DOI: https://doi.org/10.1007/s00701-010-0708-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Object

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2010

An alternative projection for fluoroscopic-guided needle insertion in the foramen ovale: technical note

Long-term facial nerve function evaluation following surgery for large acoustic neuromas via retrosigmoid transmeatal approach

Training in endoscopic endonasal transsphenoidal surgery using a skull model and eggs

Intramedullary high signal intensity and neurological status as prognostic factors in cervical spondylotic myelopathy

Clinicopathological characteristics in patients presenting with acute onset of symptoms caused by Rathke’s cleft cysts